Table 3.
Overview of adverse events*
| Patients with AEs | 50 mg SC TE (n = 14) | 100 mg SC TE (n = 15) | 200 mg IM TE (n = 10) |
|---|---|---|---|
| n (%) | n (%) | n (%) | |
| Patients with a TEAE | |||
| Any TEAE | 6 (42.9) | 7 (46.7) | 0 (0.0) |
| Any drug‐related TEAE | 2 (14.3) | 2 (13.3) | 0 (0.0) |
| Patients with an SAE | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Treatment–emergent SAE | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Drug‐related SAE | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Deaths | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Discontinuations because of TEAE | 0 (0.0) | 0 (0.0) | 0 (0.0) |
*An AE was considered to be a TEAE if the AE started on or after the first dosing of study medication. Percentage was calculated using the number of patients in the column heading as the denominator. AE = adverse event; IM = intramuscular; SAE = serious adverse event; SC = subcutaneous; TE = testosterone enanthate; TEAE = treatment‐emergent adverse event